DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Telcagepant is an investigational drug.
There have been 11 clinical trials for Telcagepant. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2007.
The most common disease conditions in clinical trials are Migraine Disorders, Heart Diseases, and Coronary Disease. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].
Recent Clinical Trials for Telcagepant
|Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)||Merck Sharp & Dohme Corp.||Phase 2/Phase 3|
|Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)||Merck Sharp & Dohme Corp.||Phase 1|
|A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046)||Merck Sharp & Dohme Corp.||Phase 2|